The Effectiveness of Adrenocorticotropin Repeated Doses in High Risk PregnanciesKlimek M.
Department of Gynecology and Infertility Clinic of Jagiellonian University, Krakow, Poland
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objective: The aim of this study was to assess the effect of two kinds of adrenocorticotropin (ACTH)-depot repeated doses administered to pregnant women who underwent infertility treatment. Material and Methods: The study population included 424 pregnant women with singletons. Two hundred and forty-two women received repeated 0.5 mg doses of ACTH, whereas 182 women also were treated for infertility but did not receive any therapy. The ACTH-treated patients were subdivided into two subgroups: (1) 142 patients received only series of three 0.5 g ACTH-depot injections every other day in the first and/or second trimester with occasionally single ACTH-depot doses in the third trimester, (2) 100 patients received only single 0.5 mg ACTH-depot doses for the entire duration of pregnancy. Clinical symptoms of threatened abortion and preterm delivery as well as very low or decreasing levels of serum oxytocinases were indications for the hormonal therapy. Low oxytocinase serum levels, recurrent abortion and preterm delivery characterize pregnant women with hypothalamic insufficiency. Results: Women who received only single doses of the ACTH-therapy for the entire duration of pregnancy had a statistically significant longer gestation, and higher newborn mass and length than patients who received a series of three hormonal injections as well as control women who had no clinical or laboratory indication for such therapy. Conclusions: ACTH-depot injection results in the oxytocinase increased serum level, a decreased number of abortion and preterm deliveries and prolonged duration of pregnancy. Single repeated doses of the ACTH-depot therapy had statistically significant better results in the prolongation of pregnancy, newborn mass and length than a serial hormonal dosage.
© 2006 S. Karger AG, Basel
- Klimek R: Pregnancy and labor in the light of studies on the oxytocin-oxytocinase system. Folia Med Cracov 1964;6:471–482.
Liggins GC, Howie RN: A controlled trial of antepartum treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972;192:515–519.
- Abbasi S, Hirsh D, Davis J, et al: Effect of single versus multiple courses of antenatal corticosteroids on maternal and neonatal outcome. Am J Obstet Gynecol 2000;182:1243–1249.
- Banks BA, Cnaan A, Morgan MA, et al: Multiple courses of antenatal corticosteroids and outcome of premature neonates. North American Thyrotropin-Releasing Hormone Study Group. Am J Obstet Gynecol 1999;181:709–717.
- French NP, Hagan R, Evans SF, et al: Repeated antenatal corticosteroids: size at birth and subsequent development. Am J Obstet Gynecol 1999;180:114–121.
Klimek R, Fedor-Freybergh P, Janus L, Walas-Skolicka E: A Time to be Born. Krakow, Dream Publishing Company, 1996.
Klimek R: Monitoring of Pregnancy and Prediction of Birth Date. New York, London, Parthenon, 1994.
Cosmi EV, Klimek R, DiRenzo GC, Kulakov V, Kurjak A, Maeda K, Mandruzzato GP, Van Gelin HP, Wladimiroff J: Prognosis pf birth term: recommendation on current practice and overview of new developments. Arch Perinat Med 1997;3:31–50.
- Klimek R: Enzymes: the most important markers of pregnancy development. J Early Pregnancy 2000;4:219–229.
- Klimek R, Bieniasz A: Studies on the relation between serum oxytocinase and labor. Am J Obstet Gynecol 1969;104:959–963.
- Klimek R: Relative duration of human pregnancy and oxytocin therapy. Gynecologia 1967;163:48–55.
- Klimek R, Drewniak K, Bieniasz A: Further studies on the oxytocin-oxytocinase system. Am J Obstet Gynecol 1969;105:427–430.
- Klimek R, Drozdz H, Zdebski Z: The enzymatic control of gestation development in patients treated with ACTH. Ginekol Pol 1967;38:1115–1121.
Klimek M, Klimek R, Mazanek-Moscicka M: Biological diagnosis and prognosis in practical obstetrics. Pol J Gynecol Invest 1999;2:57–66.
- Klimek M: Enzymatic monitoring of pregnancy. Prenat Neonat Med 2001;6:290–296.
Klimek R: Clinical studies on the balance of isooxytocinase in the blood of pregnant women. Clin Chim Acta 1968;20:235–238.
- Klimek R, Klimek M, Rzepecka-Weglarz B: A new score for postnatal clinical assessment of fetal maturity in newborn infants. Int J Obstet Gynecol 2000;71:101–105.
- Klimek M, Wicherek L, Popiela TJ, Skotniczny K, Tomaszewska B: Changes of maternal ACTH and oxytocinase plasma concentrations during the first trimester of spontaneous abortion. Neuroendocrinol Lett 2005;26:342–346.
- Magiakou MA, Mastorakos G, Rabin D, Margioris AN, Dubbert B, Calogero AE, Tsigos C, Munson PJ, Chrousos GP: The maternal hypothalamic-pituitary-adrenal axis in the third trimester of human pregnancy. Clin Endocrinol 1996;44:419–428.
- Marinoni E, Korebritis C, Di Iorio R, Cosmi EV, Challis JR: Effect of betamethason in vivo on placental corticotropin-releasing hormone in human pregnancy. Am J Obstet Gynecol 1998;178:770–778.
- Raffin-Sanson ML, Massias JF, Ankotche A, Coste J, de Keyzer Y, Oliver C, Dumont C, Carbol D, Ferre F, Bertagna X: High precursor level on maternal blood results from the alternate mode of proopiomelanocortin processing in human placenta. Clin Endocrinol 1999;50:85–94.
- Klimek R: ACTH-depot therapy in pregnant women with repeated pregnancy wastage. Eur J Obstet Gynecol Reprod Biol 1988;28:167–169.
Klimek R Paradysz A: L’insuffisance hypothalamique de la grossesse: une indication du traitment par L’ACTH syntetique. Rev Fr Endocrinol Clin 1971;3:243–249.
- Klimek R, Krzysiek J, Paradysz A, Stanek J: Blood oxytocinase and phosphatases levels in pregnant women treated with Synacthen-Depot. Endocrinol Pol 1978;29:121–129.
- Klimek M: Comparative analysis of ACTH end oxytocinase plasma concentration during pregnancy. Neuroendocrinol Lett 2005;26:337–341.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.